Clinical Scorecard: The Role of Beta-Blockers in Post-Myocardial Infarction Care: A Return to Clinical Practice
At a Glance
Category
Detail
Condition
Post-myocardial infarction with preserved left ventricular function
Key Mechanisms
Beta-blockers reduce mortality potentially via lowering blood pressure and resting heart rate, both established cardiovascular risk factors
Target Population
Patients post-MI with preserved or mildly reduced ejection fraction (>40%) without heart failure
Care Setting
Secondary prevention in outpatient or long-term cardiac care
Key Highlights
Beta-blockers associated with an 11% reduction in all-cause mortality in observational studies of post-MI patients without heart failure and EF >40%.
Randomized controlled trials in low-risk populations did not show survival benefit, but were underpowered compared to large observational data.
Discontinuation of beta-blockers in stabilized post-MI patients with preserved LV function linked to increased risk of rehospitalization and adverse outcomes.
Guideline-Based Recommendations
Diagnosis
Identify post-MI patients with preserved or mildly reduced EF (>40%) and no heart failure for consideration of beta-blocker therapy.
Management
Continue beta-blocker therapy in post-MI patients with preserved LV function who have tolerated treatment for several months or years.
Avoid interruption of beta-blockers in stabilized patients as discontinuation may increase risk of adverse cardiovascular events.
Monitoring & Follow-up
Monitor blood pressure and resting heart rate as indicators of beta-blocker efficacy and cardiovascular risk reduction.
Observe for tolerance and adverse effects to maintain adherence.
Risks
Potential increased risk of rehospitalization for angina or heart failure upon beta-blocker withdrawal.
No significant impact on hard endpoints or quality of life observed with beta-blocker interruption in low-risk patients.
Patient & Prescribing Data
Over 290,000 post-MI patients without heart failure and EF >40%, mostly from observational studies
Beta-blocker continuation associated with mortality benefit; interruption linked to increased adverse events; tolerance generally excellent
Clinical Best Practices
Maintain beta-blocker therapy in post-MI patients with preserved LV function who have tolerated treatment.
Consider beta-blockers as part of comprehensive secondary prevention including reperfusion, antiplatelet, and lipid-lowering therapies.
Use randomized trial data and large observational evidence to guide individualized patient decisions.
Monitor heart rate and blood pressure as surrogate markers for beta-blocker benefit.
In a target-trial emulation of more than 600,000 veterans, GLP-1 RA initiators saw fewer new substance use disorders—and patients with existing SUDs had fewer overdoses, hospitalizations, and deaths.
